Silence Therapeutics PLC - novel RNA therapeutics developer with offices in London and Berlin - Pretax loss widens to GBP22.6 million for six months that ended June from GBP13.3 million in the same period last year. Half-year revenue GBP5.8 million, up from GBP1.1 million. Proposes no interim dividend, unchanged.
"The first half of 2021 was marked by strong execution, highlighted by the first clinical data from our proprietary mRNAi GOLD platform that successfully translated results from pre-clinical models into humans. In addition to achieving positive clinical data from our platform, we started dosing patients in two wholly owned programs and added two new targets to our partnered pipeline," says Chief Executive Mark Rothera.
Interim revenue from collaborations is GBP5.8 million, up from GBP1.1 million last year, driven by collaboration with AstraZeneca PLC and Mallinckrodt PLC. Starts work on second undisclosed target with AstraZeneca, and on track to start work on five disease targets in next three years for cardiovascular, renal, metabolic, and respiratory diseases.
Current stock price: 604.88 pence
Year-to-date change: up 18%
By Josie O'Brien; josieobrien@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
